Results 81 to 90 of about 736,142 (286)

Survivin and Aurora Kinase A control cell fate decisions during mitosis

Molecular Oncology, EarlyView.
Aurora A interacts with survivin during mitosis and regulates its centromeric role. Loss of Aurora A activity mislocalises survivin, the CPC and BubR1, leading to disruption of the spindle checkpoint and triggering premature mitotic exit, which we refer to as ‘mitotic slippage’.
Hana Abdelkabir, Shalitha Wickrama Arachchige, Sally P. Wheatley   +2 more
wiley   +1 more source

Dissecting the Role of the FGF19-FGFR4 Signaling Pathway in Cancer Development and Progression

Frontiers in Cell and Developmental Biology, 2020
Fibroblast growth factor (FGF) receptor 4 (FGFR4) belongs to a family of tyrosine kinase receptor. FGFR4 is highly activated in certain types of cancer and its activation is closely associated with its specific ligand, FGF19.
Yanan Liu, Meng Cao, Yuepiao Cai, Xiaokun Li, Chengguang Zhao, Chengguang Zhao, Chengguang Zhao, Ri Cui, Ri Cui, Ri Cui   +9 more
doaj   +1 more source

CDK11 inhibition induces cytoplasmic p21WAF1 splice variant by p53 stabilisation and SF3B1 inactivation

Molecular Oncology, EarlyView.
CDK11 inhibition stabilises the tumour suppressor p53 and triggers the production of an alternative p21WAF1 splice variant p21L, through the inactivation of the spliceosomal protein SF3B1. Unlike the canonical p21WAF1 protein, p21L is localised in the cytoplasm and has reduced cell cycle‐blocking activity.
Radovan Krejcir, Lukasz Arcimowicz, Lucia Martinkova, Vaclav Hrabal, Filip Zavadil Kokas, Tomas Henek, Martina Kucerikova, Ondrej Bonczek, Pavlina Zatloukalova, Lenka Hernychova, Philip J. Coates, Borivoj Vojtesek, David P. Lane   +12 more
wiley   +1 more source

Histologically Malignant Solitary Fibrous Tumour of the Anterior Thoracic Wall: A Case Report and Review of the Literature

Case Reports in Medicine, 2010
Solitary fibrous tumour (SFT) is a rare oncological entity that most often arises in the pleura. Over the past 10 years, the tumour has been described at numerous extrapleural locations.
Maria Archontaki, Dimitris P. Korkolis, Niki Arnogiannaki, Stelios Hatzijiannis, Panagiotis Dendrinos, Christos Megapanos, Dimitris Kassotakis, Georgios Kokkalis   +7 more
doaj   +1 more source

Overcoming the Specific Toxicity of Large Plasmids Electrotransfer in Primary Cells In Vitro

Molecular Therapy: Nucleic Acids, 2016
Gene electrotransfer is a safe and efficient nonviral technique for the transfer of nucleic acids of all sizes. Using a small reporter plasmid (3.5 kbp), electrotransfer of more than 90% of the cells, with ≃70% viability, can be routinely achieved even ...
Léa L Lesueur, Lluis M Mir, Franck M André   +2 more
doaj   +1 more source

Inhibition of HIF-1 alpha by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma [PDF]

, 2015
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are ...
Acland, Assenat, Bazhin, Carbone, Chaput, Chen, Chouaib, Danenberg, David, Dyson, El-Deiry, Gallick, Gelovani, Ghansah, Giese, Gil, Gress, Gribben, Hao, Hao, Hao, Henson, Jemal, Kiessling, Kroemer, Kroemer, Kroemer, Levi, Luo, Mi, Moses, Plate, Powis, Powis, Powis, Ravichandran, Ricci, Rodeck, Sarker, Schuler, Semenza, Singh, Spisek, Tani, Vandenabeele, Wang, Wang, Zitvogel, Zitvogel, Zitvogel   +49 more
core   +1 more source

Reduced vascular leakage correlates with breast carcinoma T regulatory cell infiltration but not with metastatic propensity

Molecular Oncology, EarlyView.
A mouse model for vascular normalization and a human breast cancer cohort were studied to understand the relationship between vascular leakage and tumor immune suppression. For this, endothelial and immune cell RNAseq, staining for vascular function, and immune cell profiling were employed.
Liqun He, Chiara Testini, Neda Hekmati, Altea Bonello, Aglaia Schiza, Emmanuel Nwadozi, Mia Phillipson, Carina Strell, Michael Welsh   +8 more
wiley   +1 more source

The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent

Frontiers in Immunology, 2018
In spite of impressive response rates in multiple cancer types, immune checkpoint inhibitors (ICIs) are active in only a minority of patients. Alternative strategies currently aim to combine immunotherapies with conventional agents such as cytotoxic ...
Chloé Grasselly, Chloé Grasselly, Morgane Denis, Morgane Denis, Aurore Bourguignon, Aurore Bourguignon, Nolan Talhi, Doriane Mathe, Anne Tourette, Laurent Serre, Lars Petter Jordheim, Eva Laure Matera, Charles Dumontet, Charles Dumontet   +13 more
doaj   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Bright spots in the darkness of cancer: A review of starfishes-derived compounds and their anti-tumor action [PDF]

, 2019
The fight against cancer represents a great challenge for researchers and, for this reason, the search for new promising drugs to improve cancer treatments has become inevitable.
Arizza V., Lazzara V., Luparello C., Mauro M., Vazzana M.   +4 more
core   +1 more source